Floatz logo

Red Blood Cells

Relapsing-Remitting Multiple Sclerosis

Cellerys AGCell therapyPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

70 Active assets in the Relapsing-Remitting Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fingolimod
TG Therapeutics, Inc.
Phase 4BBB
Glatiramer
University Hospital, Montpellier
Phase 4BBB
Natalizumab
Biogen
Phase 4BBB
Interferon ?1 (Human Fibroblast Protein Moiety)
Biogen
Phase 4BBB
Cladribine
Uppsala University
Phase 4BBB

View all 50 →

Same molecule, other indications

Red Blood Cells is also rated in:

beta-thalassemia majorDormant
B
Indicative · Phase 3
62 / 100
View asset →
bronchopulmonary dysplasiaActive
D
Indicative · N/A
30 / 100
View asset →
hereditary persistence of fetal hemoglobinActive
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →